Dr. Joshua Richter discusses the rationale behind prioritizing BCMA-directed CAR T-cell therapy before BCMA-directed bispecific antibodies in eligible patients with multiple myeloma, reflecting current International Myeloma Working Group considerations.
Dr. Joshua Richter introduces the discussion with Dr. Doris Hansen, outlining the evolving role of CAR T-cell therapy in early relapsed/refractory multiple myeloma, with a focus on treatment sequencing, patient selection, bridging therapy, toxicity management, and emerging cellular therapies.
Doris Hansen, MD, discusses the utilization of BCMA-directed therapy in multiple myeloma.
Doris Hansen, MD, discusses the promise of ALLO-715 in relapsed/refractory multiple myeloma. Scroll to 0:07 in the video for Dr. Hansen's topline points on the agent.
Doris Hansen, MD, discusses the progression-free survival benefit yielded by idecabtagene vicleucel on the phase 2 KarMMa trial in patients with pretreated relapsed/refractory multiple myeloma.
